Viagra may also reduce the risk of developing Alzheimer’s or dementia. While this link isn’t causative, the new research opens the door for clinical…
Analysts had high hopes for anti-amyloid drug Aduhelm — the first Alzheimer’s treatment approved by the FDA in nearly two decades and the first…
Anti-amyloid drug Aduhelm has been mired in controversy surrounding its U.S. approval and its questionable efficacy. After news that the drug underperformed estimated sales…
Following the approval of the Alzheimer’s drug Aduhelm — and the litany of controversy surrounding it — one question that’s top of mind for…
Almost 60 percent of people with Alzheimer’s also show signs of seizure-like brain activity. In total, more than one fifth of people with Alzheimer’s…
Analyzing large databases of human data, scientists identified a “water pill” called bumetanide, which reduced the risk of developing Alzheimer’s for people with a…
The amyloid hypothesis—the idea that Alzheimer’s is caused by clumps of proteins known as beta-amyloid—remains unproven. But scientists are holding out hope that monoclonal…
The biotechnology company Eisai Co., Ltd. announced a rolling submission for accelerated approval from the Food and Drug Administration for their anti-amyloid Alzheimer’s treatment,…
Early data presented by Cassava Sciences demonstrates the safety of their Alzheimer’s drug simufilam, which is currently in Phase 3 clinical trials. But in late…
The biotechnology company Cassava Sciences — makers of simufilam, an anti-Alzheimer’s drug currently in Phase III clinical trials — was accused of scientific misconduct…
Whether it be coping with the cognitive, behavioral or psychological symptoms of dementia, adapting caregiver strategies throughout the different stages of the illness is…
Scientists in the field of Alzheimer’s have struggled to carry promising findings in mice studies into human trials, but primate researchers believe that animals…
Cassava Sciences revealed positive clinical data from their simufilam trial, a potentially disease-modifying therapy for treating Alzheimer’s. Their preliminary study showed that simufilam significantly…
In June, the U.S. Food and Drug Administration (FDA) approved the first new drug for treating Alzheimer’s disease in almost 20 years. The drug,…
Today, the experimental Eli Lilly drug donanemab received the FDA’s “breakthrough therapy designation” based on its potential to treat Alzheimer’s disease. The FDA granted…